SCHEMBL12744445

SCHEMBL12744445

CNS(=O)(=O)CCN1CCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
KDM1A O60341 1/20 0.43
ALOX15 P16050 1/20 0.38
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
NPC1 O15118 1/20 0.36
MBTD1 Q05BQ5 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2D6 P10635 2/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12744429 0.98 CARM1 (0.45) CARM1PRMT6PRMT8KDM1AALOX15
SCHEMBL23464921 0.91 KDM1A (0.46) CARM1PRMT6PRMT8KDM1AALOX15
SCHEMBL13451388 0.85 KDM1A (0.43) KDM1ACA1CA2CA9SMN1; SMN2
SCHEMBL12744432 0.82 KDM1A (0.41) KDM1ACA2POLB
SCHEMBL5720724 0.82 MEN1 (0.47) KDM1ACA12CA1CA2CA9
SCHEMBL12744436 0.80 KDM1A (0.43) KDM1AHRH3
SCHEMBL13008910 0.79 CARM1 (0.39) CARM1PRMT6PRMT8ALOX15CA12
SCHEMBL12744430 0.79 KDM1A (0.48) CARM1PRMT6PRMT8KDM1AALOX15
SCHEMBL14074449 0.78 SMN1; SMN2 (0.39) CARM1PRMT6PRMT8ALOX15CA12
SCHEMBL12744428 0.77 PIK3CD (0.44) KDM1AHRH3CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910611-B2 Therapeutic agent for restenosis KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-22 US disclosed
US-20100029625-A1 Therapeutic Agent for Restenosis KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029625-A1 Therapeutic Agent for Restenosis NR1H2, NR1H3, LDLR CARM1 846/4885PRMT6 1033/4885PRMT8 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.